Previous 10 | Next 10 |
Morphic Holding Inc. (MORF) is expected to report $-0.98 for Q3 2023
NEW YORK, NY / ACCESSWIRE / October 11, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF). Investors who purchased Morphic securities are encouraged to obtain additional info...
WALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the complet...
ATLANTA, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Morphic Holding, Inc. (“Morphic” or “the Company”) (NASDAQ: MORF) complied with federal securities laws. On September 22, 2023, the Company released abstract data from its EME...
2023-09-29 09:59:40 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) BofA Securities: Which small cap non-earner stocks to avoid Health Care Select Sector SPDR ETF declares quarterly distribution of $0.53...
2023-09-28 17:02:15 ET Summary Morphic Holding, Inc.'s stock has dropped 61% in just 2 months, calling into question its $3bn valuation. The company's lead asset, MORF-057, targets the integrin α4β7, but faces tough competition from the biologic drug Vedolizumab. ...
2023-09-27 05:47:01 ET Related stories MillerKnoll, Inc. (MLKN) Q1 2024 Earnings Call Transcript MillerKnoll Stock: On A Roll Cardiff Oncology (CRDF) Investor Presentation - Slideshow Connecting The Dots: Markets React To Hawkish Revisions In The Fed's Intere...
2023-09-26 16:44:17 ET More on Morphic Seeking Alpha’s Quant Rating on Morphic Historical earnings data for Morphic Financial information for Morphic Morphic: High Valuation Not Justified By Data, Development Status, Or Cash Morphic cut to Neut...
WALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Morphic Holdings Inc. (Nasdaq: MORF) today announced that Chief Executive Officer Dr. Praveen Tipirneni suffered an emergent medical event and is taking a medical leave of absence. Dr. Tipirneni is expected to return to his role as Chief Exec...
2023-09-25 14:56:13 ET Extending a sharp decline from last week, Morphic Holding ( NASDAQ: MORF ) continued to trade lower Monday as BTIG downgraded the biotech, citing questions on the potential of its lead asset, MORF-057, targeted at ulcerative colitis (UC). The analyst Jul...
News, Short Squeeze, Breakout and More Instantly...
Morphic Holding Inc. Company Name:
MORF Stock Symbol:
NYSE Market:
WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biotechnology company developing a new generation of oral...
WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will take part in a fireside c...
-α4β7 Inhibition Rapidly Increases the Rolling Velocity and Flux of B Cells in Gut-associated Lymphoid Tissues- -Impact of Potent and Selective Small Molecule Inhibitor Comparable to Monoclonal Antibody Activity- -Preclinical Findings Presented at Digestive Disease...